...
首页> 外文期刊>Iranian Journal Of Allergy, Asthma and Immunology >Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis
【24h】

Downregulation of Immunosuppressive Molecules, PD-1 and PD-L1 but not PD-L2, in the Patients with Multiple Sclerosis

机译:多发性硬化症患者中免疫抑制分子PD-1和PD-L1但不是PD-L2的下调

获取原文
           

摘要

Programmed cell death-1 (PD-1) and its ligands, PD-L1 and PD-L2, have been regarded as important immune system regulatory molecules. The aberrant expression of the molecules has been related to several autoimmune disorders. This study is aimed to assess the mRNA expression level of PD-1, PD-L1, and PD-L2 molecules in the peripheral blood mononuclear mells (PBMCs) from multiple sclerosis (MS) patients. PBMCs were isolated from the whole blood of 50 MS and 50 healthy individuals. Total RNA content of the leukocytes was extracted. Then, cDNA was synthesized from the extracted RNA. Afterwards, quantitative analysis of PD-1, PD-L1 and PD-L2 was carried out through Real Time PCR using the TaqMan gene expression assays. Relative expression of PD-1 and PD-L1 in PBMCs from MS patients was significantly lower compared with the healthy control group (p=0.003 and 0.012, respectively). However, no significant difference was observed in the expression level of PD-L2 between patients and healthy individuals. Relative expression of PD-1 correlated with expanded disability status scale score (EDSS) of the patients (r=-0.763,?p=0.008). Downregulation of the immunosuppressive molecules, PD-1 and PD-L1, may imply that over-activation of immune cells in multiple sclerosis occurs through signaling dysfunction of these molecules and PD-L2 plays no important role in this context.
机译:程序性细胞死亡1(PD-1)及其配体PD-L1和PD-L2被认为是重要的免疫系统调节分子。分子的异常表达与几种自身免疫性疾病有关。这项研究旨在评估多发性硬化症(MS)患者外周血单个核细胞(PBMC)中PD-1,PD-L1和PD-L2分子的mRNA表达水平。从50名MS和50名健康个体的全血中分离出PBMC。提取白细胞的总RNA含量。然后,从提取的RNA合成cDNA。之后,使用TaqMan基因表达分析通过实时PCR对PD-1,PD-L1和PD-L2进行定量分析。与健康对照组相比,MS患者PBMC中PD-1和PD-L1的相对表达显着降低(分别为p = 0.003和0.012)。然而,在患者和健康个体之间PD-L2的表达水平没有观察到显着差异。 PD-1的相对表达与患者扩大的残疾状态量表评分(EDSS)相关(r = -0.763,?p = 0.008)。免疫抑制分子PD-1和PD-L1的下调可能意味着多发性硬化症中免疫细胞的过度激活是通过这些分子的信号功能障碍而发生的,而PD-L2在此情况下不发挥重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号